Secondly, the role of SF3A2 in inducing a suppressive immune environment and influencing the effect of immunotherapy needs to be verified in vivo and its predictive value for immunotherapy should be validated in prospective cohorts of ICB-treated CRC patients. Here, SF3A2 is linked to colorectal carcinoma.